Cancer Patients Treated by Nephrotoxic ChemotherapyNCT07123688
Diagnostic Value of Tc-99mMDP Bone Scan in Assessment of Renal Functions in Cancer Patients Compared to Estimated Glomerular Filtration Rate.
An observational study of Cancer Patients Treated by Nephrotoxic Chemotherapy, run by Assiut University.
Trial summary
-To compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate (eGFR) and assess if we can do metastatic work up and evaluate renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer Patients Treated by Nephrotoxic Chemotherapy
- What is being tested?
- Tc-99mMDP bone scan
- Type of treatment
- Medical device
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2025to 1 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult patients with a known history of malignancy treated by nephrotoxic chemotherapy who are referred to do bone scan as a part of the metastatic workup.
Who may be able to join
- Adult patients with a known history of malignancy treated by nephrotoxic chemotherapy as Cisplatin, who are referred to do bone scan as a part of the metastatic workup. These patients must have recent renal function including serum creatinine, in order to calculate estimated glomerular filtration rate (eGFR) (no chemotherapy is given after the recorded renal function). History of renal problems, previous surgery or medical treatment for the kidney will be reported. Type, duration and dose of chemotherapy also will be reported.
Who cannot join
- Patients with known renal failure,Patients refuse to do the scan,Patients with relative or absolute contraindications to do the scan (eg. pregnancy).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
HebatAllah Ahmed AbdelRaoof Askar, Assistant Professor, doctor contact
About this study
Official title: Diagnostic Value of Tc-99mMDP Bone Scan in Assessment of Renal Functions in Cancer Patients Compared to Estimated Glomerular Filtration Rate (eGFR).
-To compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate (eGFR) and assess if we can do metastatic work up and evaluate renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure.
Read the detailed description
- Bone scan is one of the frequently used imaging tests in nuclear medicine. It is applied as a test for some oncologic and non-oncologic diseases; the common use is for the detection of bone metastasis from malignant tumors. Renal function may worsen with increasing age, co-morbidities like diabetes, hypertension, acute loss of weight and muscle mass, dehydration and long term use of non-steroidal inflammatory drugs and after some malignancies like multiple myeloma. Therefore renal function assessment is important and can be done by glomerular filtration rate using dGFR. Such a method uses technetium-99m-diethyl-triamine-penta-acetic acid (99mTc-DTPA). Other methods are SCR levels and estimated glomerular filtration rate (eGFR). The use of nephrotoxic drugs such as cisplatin is one of the chemotherapeutic agents in the treatment of a variety of solid tumors; however, it has a side effect of nephrotoxicity. In addition, methotrexate is primarily excreted by the kidneys and estimate of renal function is essential before the use of high-dose therapy.
- Glomerular filtration rate indicates creatinine clearance (CrCl), i.e., a ratio of the concentration of creatinine in serum and urine. Serum creatinine and CrCl have the leading role in the early diagnosis, monitoring and classification of chronic renal insufficiency. MDRD equation may be used for the estimation of glomerular filtration rate, which is accepted due to its simplicity, economic viability and acceptable performance. The most commonly used formula is the "4-varibale MDRD," which estimates GFR using four variables: Serum creatinine, age, race and gender.
- Information about the kidneys can be obtained from bone scan because Tc-99mMDP is excreted through the kidneys. Tc-99mMDP can be an alternative to Tc-99mDTPA for evaluating renal function while conducting bone metastases surveys in patients with urinary tract malignancy with reduced cost and radiation exposure.
- The study aims to investigate the use of Tc-99mMDP for assessing glomerular filtration rate to assess metastatic work up and renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure.
- Being tested
- Tc-99mMDP bone scan
- Keywords
- bone scan , renal functions , eGFR
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tc-99mMDP bone scanDevice
5 mCi of Tc-99mMDP is used for dynamic renography followed by 15 mCi for post 3-hr whole body imaging.
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate in cancer patients treated by nephrotoxic drugs.
Compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate (eGFR) in adult patients with a known history of malignancy treated by nephrotoxic chemotherapy as Cisplatin, who are referred to do bone scan as a part of the metastatic workup, to evaluate renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure
Measured: from 1 /10/2025 to 1/10/2027
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2025
- Study start1 Oct 2025 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Cancer Patients Treated by Nephrotoxic ChemotherapyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aya Kamel Hamed Ahmed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07123688
- Sponsor's protocol ID
- bone scan in cancer patients
- Status last verified
- Aug 2025
- First submitted
- 8 Aug 2025
- Last updated
- 14 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Alqahtani MM. Cisplatin-Induced Renal Failure Measured by Glomerular Filtration Rate (GFR) with 99mTc-DTPA Scans in Cancer Patients: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2024 Nov 5;14(22):2468. doi: 10.3390/diagnostics14222468.
PubMed 39594134Javaid A, Munir I, Jaffri SA, Qazi MH, Nawaz MK. A comparison between estimates of glomerular filtration rate using technetium-99m-diethylene-triamine-pentaacetic acid clearance and modification of diet in renal disease equation. Saudi Journal of Medicine & Medical Sciences. 2014;2(3):157-61.
Badawy AM, El-Sayed ND, Mohamed OA, Nassar SA, Osman MO. The value of Tc-99mMDP bone scan in assessment of renal functions in urinary tract neoplasm patients after chemotherapy compared toTc-99mDTPA renal scan. Egyptian Journal Nuclear Medicine. 2024;29(2):61-9
Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT. Diagnostic bone scanning in oncology. Semin Nucl Med. 1997 Apr;27(2):107-41. doi: 10.1016/s0001-2998(97)80043-8.
PubMed 9144855
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic Value of Tc-99mMDP Bone Scan in Assessment of Renal Functions in Cancer Patients Compared to Estimated Glomerular Filtration Rate (eGFR).
- ClinicalTrials.gov ID
- NCT07123688
- Acronym / sponsor ID
- bone scan in cancer patients
- Keywords
- bone scan , renal functions , eGFR
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Oct 2025 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 14 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
-To compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate (eGFR) and assess if we can do metastatic work up and evaluate renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure.
Detailed description
- Bone scan is one of the frequently used imaging tests in nuclear medicine. It is applied as a test for some oncologic and non-oncologic diseases; the common use is for the detection of bone metastasis from malignant tumors. Renal function may worsen with increasing age, co-morbidities like diabetes, hypertension, acute loss of weight and muscle mass, dehydration and long term use of non-steroidal inflammatory drugs and after some malignancies like multiple myeloma. Therefore renal function assessment is important and can be done by glomerular filtration rate using dGFR. Such a method uses technetium-99m-diethyl-triamine-penta-acetic acid (99mTc-DTPA). Other methods are SCR levels and estimated glomerular filtration rate (eGFR). The use of nephrotoxic drugs such as cisplatin is one of the chemotherapeutic agents in the treatment of a variety of solid tumors; however, it has a side effect of nephrotoxicity. In addition, methotrexate is primarily excreted by the kidneys and estimate of renal function is essential before the use of high-dose therapy.
- Glomerular filtration rate indicates creatinine clearance (CrCl), i.e., a ratio of the concentration of creatinine in serum and urine. Serum creatinine and CrCl have the leading role in the early diagnosis, monitoring and classification of chronic renal insufficiency. MDRD equation may be used for the estimation of glomerular filtration rate, which is accepted due to its simplicity, economic viability and acceptable performance. The most commonly used formula is the "4-varibale MDRD," which estimates GFR using four variables: Serum creatinine, age, race and gender.
- Information about the kidneys can be obtained from bone scan because Tc-99mMDP is excreted through the kidneys. Tc-99mMDP can be an alternative to Tc-99mDTPA for evaluating renal function while conducting bone metastases surveys in patients with urinary tract malignancy with reduced cost and radiation exposure.
- The study aims to investigate the use of Tc-99mMDP for assessing glomerular filtration rate to assess metastatic work up and renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patients with a known history of malignancy treated by nephrotoxic chemotherapy who are referred to do bone scan as a part of the metastatic workup.
Key inclusion criteria (1 listed)
- Adult patients with a known history of malignancy treated by nephrotoxic chemotherapy as Cisplatin, who are referred to do bone scan as a part of the metastatic workup. These patients must have recent renal function including serum creatinine, in order to calculate estimated glomerular filtration rate (eGFR) (no chemotherapy is given after the recorded renal function). History of renal problems, previous surgery or medical treatment for the kidney will be reported. Type, duration and dose of chemotherapy also will be reported.
Key exclusion criteria (1 listed)
- Patients with known renal failure,Patients refuse to do the scan,Patients with relative or absolute contraindications to do the scan (eg. pregnancy).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tc-99mMDP bone scan5 mCi of Tc-99mMDP is used for dynamic renography followed by 15 mCi for post 3-hr whole body imaging. | Device | – |
Primary outcome
Compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate in cancer patients treated by nephrotoxic drugs.
Time frame: from 1 /10/2025 to 1/10/2027
Compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate (eGFR) in adult patients with a known history of malignancy treated by nephrotoxic chemotherapy as Cisplatin, who are referred to do bone scan as a part of the metastatic workup, to evaluate renal function at a single Tc-99mMDP study, thereby reducing cost, time and radiation exposure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2025.
- Results publication: PubMed 39594134Alqahtani MM. Cisplatin-Induced Renal Failure Measured by Glomerular Filtration Rate (GFR) with 99mTc-DTPA Scans in Cancer Patients: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2024 Nov 5;14(22):2468. doi: 10.3390/diagnostics14222468.
- Results publicationJavaid A, Munir I, Jaffri SA, Qazi MH, Nawaz MK. A comparison between estimates of glomerular filtration rate using technetium-99m-diethylene-triamine-pentaacetic acid clearance and modification of diet in renal disease equation. Saudi Journal of Medicine & Medical Sciences. 2014;2(3):157-61.
- Results publicationBadawy AM, El-Sayed ND, Mohamed OA, Nassar SA, Osman MO. The value of Tc-99mMDP bone scan in assessment of renal functions in urinary tract neoplasm patients after chemotherapy compared toTc-99mDTPA renal scan. Egyptian Journal Nuclear Medicine. 2024;29(2):61-9
- Results publication: PubMed 9144855Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT. Diagnostic bone scanning in oncology. Semin Nucl Med. 1997 Apr;27(2):107-41. doi: 10.1016/s0001-2998(97)80043-8.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
HebatAllah Ahmed AbdelRaoof Askar, Assistant Professor, doctor contact
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer Patients Treated by Nephrotoxic Chemotherapy, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aya kamel Hamed Ahmed, Resident doctor (+2001097763423, ayakamel1744@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate in cancer patients treated by nephrotoxic drugs. (time frame: from 1 /10/2025 to 1/10/2027). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07123688, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2025.